The government will continue to engage with phage stakeholders, including through the Innovate UK Knowledge Transfer Network (KTN) Phage Innovation Network. The UK Health Security Agency (UKHSA) provides the chair for Phage Innovation Network’s scientific advisory board. UKHSA supports the goals of the network in developing phage- based products for use in clinical settings and other sectors, alongside developing links with researchers. The MHRA is working closely with the network to understand how it can support phage research and innovation. DHSC works closely with NIHR and UK Research and Innovation (UKRI) to monitor the research and clinical trial pipeline for antimicrobials and alternative therapies. Where phage research opportunities are identified, NIHR can engage researchers to encourage and support funding applications. The government is developing the 2024 to 2029 AMR NAP. The NAP will set out the government's research priorities, including innovation of new products for tackling AMR.